Key Takeaways
- • €80M evergreen fund launched: Delphinus Venture Capital, based in Aarhus, Denmark, has been established with €80 million in capital to invest in research-driven startups across East and Central Jutland, with no predetermined exit timeline.
- • University-backed consortium: The Aarhus University Research Foundation partnered with regional stakeholders HEARTLAND, Norlys, and the Salling Group to create the fund, positioning it as a bridge between academic research and commercial entrepreneurship.
- • Pre-seed to scale-up investment thesis: The fund targets startups at all stages from early-stage through late growth, distinguishing itself through long-term value creation focus rather than traditional venture fund exit pressure.
- • Experienced leadership: Mathias Brink Lorenz, former Investment Director at the European Circular Bioeconomy Fund in Germany, was appointed CEO, bringing international venture capital expertise to the initiative.
- • Strategic geographic positioning: The fund's Aarhus base ensures proximity to Aarhus University, Aarhus University Hospital, and regional research and innovation hubs, creating operational synergies with the research ecosystem.
Summary
Delphinus Venture Capital, an Aarhus-based venture fund capitalized at €80 million, has launched to catalyze startup growth across East and Central Jutland by commercializing research-driven innovation. The fund represents a collaboration between the Aarhus University Research Foundation and three regional institutional partners: HEARTLAND, Norlys, and the Salling Group. This multi-stakeholder structure reflects a strategic commitment to developing the local startup ecosystem beyond traditional venture capital models.
The fund's structural design departs from conventional venture capital practice in two material respects. First, it operates as an evergreen fund with no fixed investment horizon, eliminating pressure for predetermined exit timelines and enabling patient capital deployment. Second, it maintains investment flexibility across the full startup lifecycle, from pre-seed through scale-up stages, allowing the fund to support companies from concept validation through growth acceleration. This approach acknowledges that research commercialization typically requires extended development cycles and sustained capital commitments.
Mathias Brink Lorenz, appointed as CEO, brings substantive international experience to the role, having served as Investment Director at the European Circular Bioeconomy Fund in Germany. His appointment signals the fund's intent to apply professional venture capital discipline while maintaining its regional development mandate. Lorenz emphasized the fund's differentiation in his statement: "Unlike traditional venture funds, Delphinus has been intentionally set up with a structure that enables long-term commitment and flexibility in our investments. We can and will participate as an investor from the very early stages through to the late growth stage."
The geographic positioning of the fund creates operational advantages. By locating in Aarhus, Delphinus maintains proximity to the Aarhus University research environment, Aarhus University Hospital, and other regional innovation infrastructure. This alignment reduces information asymmetries regarding emerging research opportunities and strengthens the fund's capacity to identify and support research-intensive startups with global commercialization potential. The initiative reflects a broader trend of regional economies investing venture capital capacity to retain and scale knowledge-intensive entrepreneurship.
The fund's structural design departs from conventional venture capital practice in two material respects. First, it operates as an evergreen fund with no fixed investment horizon, eliminating pressure for predetermined exit timelines and enabling patient capital deployment. Second, it maintains investment flexibility across the full startup lifecycle, from pre-seed through scale-up stages, allowing the fund to support companies from concept validation through growth acceleration. This approach acknowledges that research commercialization typically requires extended development cycles and sustained capital commitments.
Mathias Brink Lorenz, appointed as CEO, brings substantive international experience to the role, having served as Investment Director at the European Circular Bioeconomy Fund in Germany. His appointment signals the fund's intent to apply professional venture capital discipline while maintaining its regional development mandate. Lorenz emphasized the fund's differentiation in his statement: "Unlike traditional venture funds, Delphinus has been intentionally set up with a structure that enables long-term commitment and flexibility in our investments. We can and will participate as an investor from the very early stages through to the late growth stage."
The geographic positioning of the fund creates operational advantages. By locating in Aarhus, Delphinus maintains proximity to the Aarhus University research environment, Aarhus University Hospital, and other regional innovation infrastructure. This alignment reduces information asymmetries regarding emerging research opportunities and strengthens the fund's capacity to identify and support research-intensive startups with global commercialization potential. The initiative reflects a broader trend of regional economies investing venture capital capacity to retain and scale knowledge-intensive entrepreneurship.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.